<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02606760</url>
  </required_header>
  <id_info>
    <org_study_id>PM1434</org_study_id>
    <secondary_id>2015-002365-34</secondary_id>
    <nct_id>NCT02606760</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of P-3073 Nail Solution in the Treatment of Nails Affected by Psoriasis</brief_title>
  <official_title>A Randomized, Double-blind, Vehicle-controlled, Parallel Group Trial to Assess the Efficacy, Safety and Tolerability of P-3073 for Topical Treatment of Nail Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Polichem S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Polichem S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to confirm the clinical efficacy and the safety of P-3073 in
      patients affected by isolated psoriatic nail(s) and/or those with psoriatic nails and
      concomitant mild to moderate plaque psoriasis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 23, 2015</start_date>
  <completion_date type="Actual">February 8, 2017</completion_date>
  <primary_completion_date type="Actual">February 8, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in total Nail Psoriasis Severity Index (NAPSI)</measure>
    <time_frame>Baseline - Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in NAPSI matrix</measure>
    <time_frame>Baseline - Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NAPSI bed</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nail Physician Global Assessment (PGA) response rate</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient's quality-of-life by means of the Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>Baseline - Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in discomfort by means of the Visual Analogue Scale (VAS)</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of nails with improvement in total NAPSI</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of nails with improvement in NAPSI Matrix</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of nails with improvement in NAPSI bed</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall safety by recording any AE during the entire study duration and the local tolerability by means of severity scores for skin irritation.</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">378</enrollment>
  <condition>Nail Psoriasis</condition>
  <arm_group>
    <arm_group_label>P-3073</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>P-3073</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vehicle of P-3073</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>vehicle of P-3073</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>P-3073</intervention_name>
    <arm_group_label>P-3073</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle of P-3073</intervention_name>
    <arm_group_label>vehicle of P-3073</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent before starting any study related procedures

          -  Patients aged 18 to 80 years old of any race.

          -  Males or females.

          -  Patients with mild to moderate psoriastic fingernail(s) defined as fingernail/s with
             matrix psoriasis NAPSI score and/or bed psoriasis NAPSI score ≥ 1 and ≤ 3 at baseline.

          -  In case of skin involvement, patients with established clinical diagnosis of
             mild-to-moderate psoriasis (BSA involvement ≤ 8% or PASI ≤ 10)

        Exclusion Criteria:

          -  Woman who is pregnant, nursing an infant, or planning a pregnancy during the study
             period.

          -  Use of any systemic treatment for psoriasis during the last six months before the
             screening visit.

          -  Use of photochemotherapy or other forms of radiotherapy during the last four weeks
             before the screening visit.

          -  Positive mycology findings

          -  Systemic use of immunosuppressives, chemotherapy and corticosteroids during last three
             months before the screening visit.

          -  Consumption of Vitamin D or its analogues during the last three months.

          -  History of hypercalcaemia or hypercalciuria.

          -  HIV infection or any other immunodeficiency.

          -  Alcohol or substance abuse.

          -  Patients with history of allergic reactions to calcipotriol or its excipients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maurizio Caserini, MD</last_name>
    <role>Study Director</role>
    <affiliation>Polichem S.A.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Latvia</country>
    <country>Poland</country>
    <country>Russian Federation</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2015</study_first_submitted>
  <study_first_submitted_qc>November 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2015</study_first_posted>
  <last_update_submitted>March 6, 2018</last_update_submitted>
  <last_update_submitted_qc>March 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nail psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

